2013 Malignant Hematology Research

1. 2013 Malignant Hematology Research Sales Representative and Company Image Evaluation The contents of the present report is the sole property of OncoMed Incorporated and any copying, distribution, reproduction or other such unauthorized use may not be done with out its express written consent. Private & Confidential May 2013

2. Content • Objectives and Methodology • Physician Profile • Representative Knowledge • Representative-Physician Interaction • Representative Conduct • Corporate Image • Executive Summary Content

3. Objectives and Methodology

4. Evaluate physician-representative interaction. ( “the call” ) Access representative activity. Evaluate representative knowledge. Evaluate representative conduct Assess representative activity Evaluate representative knowledge Principle Objectives To obtain hematologist/oncologist quantitative ranking of oncology sales representatives from six companies that visit them to promote medications in leukemia, lymphoma and myeloma: Objectives & Methodology To obtain hematologist/oncologist quantitative ranking of each company’s image

5. Research Parameters Physician Profile and Representative Activity Representative Knowledge Disease state Diseases Treated Patient Load Product Objectives & Methodology Location of practice Competitive landscape Formal guidelines Evidence based medicine Time spent on average with representative. Pharmacoeconomics Reps seen in total (@1 and 3 months) Reimbursement environment Specific company reps seen (National and Regional reach/frequency) Patient needs

6. Research Parameters Physician – Representative Interaction (The “call”) Representative Conduct Setting of clear objectives Follow rules to get appointment Communication skills Objectivity / Fair balance Objectives & Methodology Respect MD’s time Handling questions Acts in an ethical manner Presenting clinical data Leveraging resources Adheres to Rx+D and other regulations Follow up High value programs Two most effective companies / two least effective. Why?

7. Research Parameters Corporate Image Reputation / Trust Ease of access to company functions Objectives & Methodology Perceived coordination between company functions R & D Organizational focus on the cancer patient Quality of CME activities Meeting / conference support for physicians

8. Companies Profiled Objectives & Methodology

9. Physician Profile

10. Please indicate the province where you practice. Alberta = 4 BC = 6 Ontario = 21 Quebec = 11 NF = 1 PEI = 1 Total Responses = 47 NB = 3 Physician Profile

11. In malignant hematology, which of the following diseases do you treat? (Choose all that apply.) Physician Profile

12. Of the following companies, please indicate which oncology sales representatives (promoting medications in malignant hematology) have visited you the PAST THREE MONTHS? (Do not include visits by medical liaisons or other company delegates.) Physician Profile

13. Representative Knowledge

14. How would you rate their KNOWLEDGE of the COMPETITIVE LANDSCAPE in their respective disease state? (understanding how their drug fits in to treatment algorithms in relation to other therapies, understands how it is positioned in therapy) Clearly defines his/her objectives for meeting with you. Please indicate the province where you practice. Please indicate the province where you practice. 9 Representative Physician Interaction 7 9 8.76 8.25 8 8.20 8.66 8.62 AVG 8.49 7.89 Physician Rating Physician Rating AVG 7.94 8.43 8.39 Representative Knowledge 8 7.69 7.55 7.41 7.71 7 BMS Celgene Lundbeck Novartis Janssen Roche

15. Representative Physician Interaction

16. Rep demonstrates objectivity: Ability to present unbiased data/ “fair balance” / objectivity (i.e. not a one-sided viewpoint) Please indicate the province where you practice. 8 7.60 7.50 Physician Rating 7.47 AVG 7.38 7.35 Rep Physician Interaction 7.28 7 6.82

17. Representative Conduct

18. Please indicate the province where you practice. Company sales representative always acts in a professional and ethical manner. 9.36 9.35 9.3 9.29 AVG 9.23 9.2 Physician Rating 9.19 Representative Conduct 9.1 9.08 9.0 9.00 8.9

19. Corporate Image

20. Please indicate the province where you practice. Degree of organizational focus on the cancer patient (patient education programs, compliance programs, compassionate programs, patient reimbursement and financial assistance programs) 9.0 Physician Rating 8.42 Corporate Image 8.23 8.0 8.07 AVG 7.85 7.74 7.33 7.13 7.0

21. Contact Information Paul Hunt MSc Commercial Director OncoMed Incorporated T: (514) 892-4868 E: paul@oncomed.ca Executive Summary